Key result
In situ immune profiling of heart transplant biopsies showed significantly higher proportions of PD-L1+, FoxP3+, and CD68+ cells in 'never-rejection' compared with 'future-rejection' cases.
Why the study?
Guideline-directed histologic grading of endomyocardial biopsy tissue samples for heart transplant rejection surveillance has limited diagnostic accuracy.
Does quantitative in situ immune profiling of heart transplant biopsies improve diagnostic accuracy and rejection risk stratification compared to standard histologic grading?
Population
Retrospective cohort of clinical endomyocardial tissue samples
Comparison
Histologic grade vs clinical rejection trajectory
Design
Retrospective cohort study
Authors
Loading...
May support rejection risk stratification in transplants; leaves open whether profiling improves accuracy over standard histology.
Cohort
Does quantitative in situ immune profiling of heart transplant biopsies improve diagnostic accuracy and rejection risk stratification compared to standard histologic grading?
In situ immune profiling of heart transplant biopsies identifies specific immune cell populations that correlate with clinical rejection trajectories, potentially improving diagnostic accuracy over standard histologic grading.
Peyster et al. (2020) conducted a cohort in Cardiac allograft rejection. In situ immune profiling of PD-L1+, FoxP3+, and CD68+ cells was evaluated on Clinical rejection trajectory. In situ immune profiling of heart transplant biopsies showed significantly higher proportions of PD-L1+, FoxP3+, and CD68+ cells in 'never-rejection' compared with 'future-rejection' cases.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: